Nevolat has quickly become one of the most sought-after names in weight loss treatments in 2026, recognized as a high-potency dual GIP/GLP-1 receptor agonist very closely related to tirzepatide. Administered as a once-weekly subcutaneous injection, Nevolat works by mimicking the actions of two natural gut hormones to regulate appetite, slow gastric emptying, enhance insulin secretion […]